clexane 20mg/0.2ml solution for injection pre-filled syringes
sanofi - enoxaparin sodium - solution for injection - 100mg/1ml
clexane forte 150mg/1ml solution for injection pre-filled syringes
sanofi - enoxaparin sodium - solution for injection - 150mg/1ml
clexane forte 120mg/0.8ml solution for injection pre-filled syringes
sanofi - enoxaparin sodium - solution for injection - 150mg/1ml
clexane 100mg/1ml solution for injection pre-filled syringes
sanofi - enoxaparin sodium - solution for injection - 100mg/1ml
clexane 80mg/0.8ml solution for injection pre-filled syringes
sanofi - enoxaparin sodium - solution for injection - 100mg/1ml
clexane 60mg/0.6ml solution for injection pre-filled syringes
sanofi - enoxaparin sodium - solution for injection - 100mg/1ml
praluent 150 mgml
sanofi israel ltd - alirocumab - solution for injection - alirocumab 150 mg / 1 ml - alirocumab - primary hypercholesterolaemia and mixed dyslipidaemiapraluent is indicated in adults with primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia, as an adjunct to diet:- in combination with a statin or statin with other lipid lowering therapies in patients unable to reach ldl-c goals with the maximum tolerated dose of a statin or,- alone or in combination with other lipid-lowering therapies in patients who are statin-intolerant, or for whom a statin is contraindicated.established atherosclerotic cardiovascular diseasepraluent is indicated in adults with established atherosclerotic cardiovascular disease to reduce cardiovascular risk by lowering ldl-c levels, as an adjunct to correction of other risk factors:- in combination with the maximum tolerated dose of a statin with or without other lipid-lowering therapies or,- alone or in combination with other lipid-lowering therapies in patients who are statin-intolerant, or for whom a statin is contraindicated.
praluent 75 mgml
sanofi israel ltd - alirocumab - solution for injection - alirocumab 75 mg / 1 ml - alirocumab - primary hypercholesterolaemia and mixed dyslipidaemiapraluent is indicated in adults with primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia, as an adjunct to diet:- in combination with a statin or statin with other lipid lowering therapies in patients unable to reach ldl-c goals with the maximum tolerated dose of a statin or,- alone or in combination with other lipid-lowering therapies in patients who are statin-intolerant, or for whom a statin is contraindicated.established atherosclerotic cardiovascular diseasepraluent is indicated in adults with established atherosclerotic cardiovascular disease to reduce cardiovascular risk by lowering ldl-c levels, as an adjunct to correction of other risk factors:- in combination with the maximum tolerated dose of a statin with or without other lipid-lowering therapies or,- alone or in combination with other lipid-lowering therapies in patients who are statin-intolerant, or for whom a statin is contraindicated.
medicine administration kit, percutaneous, medicated, single-use
sanofi-aventis australia pty ltd - 45156 - medicine administration kit, percutaneous, medicated, single-use - cablivi (aust r 318058) is indicated for the treatment of adults experiencing an episode of acquired thrombotic thrombocytopenic purpura (attp), in conjunction with plasma exchange and immunosuppression. each pack contains a caplacizumab powder vial and prefilled diluent syringe supplied together with a vial adapter, needle and swabs suitable for administration. packs of 1x or 7x all components.
peppermint oil sanofi 0.2 ml gastro-resistant soft capsules
sanofi-aventis ireland limited t/a sanofi - peppermint oil - gastro-resistant capsule, soft - 0.2 millilitre(s) - other drugs for functional gastrointestinal disorders